Carisma Therapeutics has increased its series B round to $59m thanks to an extension backed by IP Group, Penn Medicine and 4Bio Capital.

Carisma Therapeutics, a US-based cancer immunotherapy spinout of University of Pennsylvania, grew its series B round to $59m yesterday following a $12m extension backed by commercialisation firm IP Group. Penn Medicine, which consists of the institution’s Perelman School of Medicine and medical care provider University of Pennsylvania Health System, also backed the second tranche, as…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.